Pritchett Allison M, Morrison John F, Edwards William D, Schaff Hartzell V, Connolly Heidi M, Espinosa Raul E
Division of Cardiovascular Diseases and Internal Medicine, Mayo Clinic, Rochester, Minn 55905, USA.
Mayo Clin Proc. 2002 Dec;77(12):1280-6. doi: 10.4065/77.12.1280.
To determine whether an association exists between pergolide and valvular heart disease.
Three patients with severe, unexplained tricuspid regurgitation were examined at our institution from September 2000 to April 2002. Echocardiography and histology of surgically explanted valves revealed abnormalities suggestive of carcinoid involvement, methysergide or ergotamine treatment, or use of fenfluramine and dexfenfluramine. Carcinoid valvular heart disease was excluded. None of the patients had prior treatment with these drugs. All 3 patients were taking pergolide.
Of the 3 patients, 2 had predominantly right-sided congestive heart failure. In all 3 patients, echocardiography showed unusual valve morphology, with severe tricuspid valve regurgitation. Significant left-sided valve regurgitation was noted in 2 patients. Histologic analysis revealed surface fibroproliferative lesions with preserved underlying valve architecture.
The echocardiographic and histopathologic features of these cases are strikingly similar to those associated with carcinoid-, ergot-, and fenfluramine-induced valve disease. An association between pergolide and valvular heart disease may therefore exist.
确定培高利特与心脏瓣膜病之间是否存在关联。
2000年9月至2002年4月期间,在我们机构对3例患有严重的、不明原因三尖瓣反流的患者进行了检查。手术切除瓣膜的超声心动图检查和组织学检查显示存在异常,提示类癌累及、麦角酰二乙胺或麦角胺治疗,或使用芬氟拉明和右芬氟拉明。排除类癌性心脏瓣膜病。所有患者此前均未接受过这些药物的治疗。所有3例患者均服用培高利特。
3例患者中,2例主要表现为右侧充血性心力衰竭。所有3例患者的超声心动图均显示瓣膜形态异常,伴有严重的三尖瓣反流。2例患者存在明显的左侧瓣膜反流。组织学分析显示表面纤维增生性病变,瓣膜结构基本保留。
这些病例的超声心动图和组织病理学特征与类癌、麦角和芬氟拉明所致瓣膜病极为相似。因此,培高利特与心脏瓣膜病之间可能存在关联。